Zymeworks BC Inc [ZYME] stock prices are up 1.56% to $15.01 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ZYME shares have gain 3.52% over the last week, with a monthly amount glided 7.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zymeworks BC Inc [NASDAQ: ZYME] stock has seen the most recent analyst activity on December 16, 2024, when JP Morgan upgraded its rating to a Overweight but kept the price target unchanged to $18 for it. Previously, Leerink Partners upgraded its rating to Outperform on November 07, 2024, and elevated its price target to $25. On November 01, 2024, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $12 on the stock. H.C. Wainwright reiterated its recommendation of a Neutral and reduced its price target to $8 on January 04, 2023. Jefferies upgraded its rating to Buy for this stock on December 20, 2022, and upped its price target to $11. In a note dated November 01, 2022, H.C. Wainwright downgraded an Neutral rating on this stock and revised its target price from $40 to $8.
The stock price of Zymeworks BC Inc [ZYME] has been fluctuating between $7.97 and $17.70 over the past year. Currently, Wall Street analysts expect the stock to reach $19.5 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $15.01 at the most recent close of the market. An investor can expect a potential return of 29.91% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
The Zymeworks BC Inc [NASDAQ:ZYME] reported sales of 62.20M for trailing twelve months, representing a drop of -3.07%. Gross Profit Margin for this corporation currently stands at -0.02% with Operating Profit Margin at -1.95%, Pretax Profit Margin comes in at -1.9%, and Net Profit Margin reading is -1.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.27 and Total Capital is 0.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 89.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.31 points at the first support level, and at 13.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.39, and for the 2nd resistance point, it is at 17.77.
Ratios To Look Out For
It’s worth pointing out that Zymeworks BC Inc [NASDAQ:ZYME]’s Current Ratio is 4.10. Also, the Quick Ratio is 4.10, while the Cash Ratio stands at 0.0. Considering the valuation of this stock, the price to sales ratio is 17.02, the price to book ratio is 2.87.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on Jan 02 ’25 when 0.16 million shares were purchased. Director, EcoR1 Capital, LLC completed a deal on Dec 31 ’24 to buy 0.15 million shares. Meanwhile, Director EcoR1 Capital, LLC bought 58988.0 shares on Dec 30 ’24.
